Literature DB >> 8253350

Comparison of clearance and metabolism of infused cholecystokinins 8 and 58 in dogs.

P Hoffmann1, G A Eberlein, J R Reeve, R H Bünte, D Grandt, H Goebell, V E Eysselein.   

Abstract

BACKGROUND: Cholecystokinin (CCK) 58 is the predominant molecular form of CCK in canine and human intestine and circulating blood. There is no report on the metabolism and clearance rate of CCK-58. The aim of this study was to compare the in vivo half-life and metabolism of CCK-58 with that of synthetic CCK-8.
METHODS: CCK-58 was purified from canine intestine by consecutive high-performance liquid chromatographic (HPLC) and fast protein liquid chromatographic steps. The peptides were given to 12 dogs as an intravenous (IV) bolus injection to determine the half-life of circulating CCK. Six dogs were given CCK-58 or CCK-8 as a constant IV infusion to determine plasma clearance rates and stability in circulating blood. Circulating molecular forms of CCK were determined by radioimmunoassay after extraction of CCK from plasma and characterization by HPLC.
RESULTS: The half-life of CCK-58 was 4.4 +/- 0.6 minutes compared with 1.3 +/- 0.1 minutes for CCK-8. Less than 5% of CCK-58 could be detected as smaller forms during constant IV infusion.
CONCLUSIONS: The longer half-life of CCK-58 compared with CCK-8 and the minimal conversion into smaller forms during constant IV infusion are consistent with the finding that CCK-58 is not only the major stored form but also the circulating form of CCK after endogenous stimulation in dogs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8253350     DOI: 10.1016/0016-5085(93)91070-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  5 in total

1.  Electrophysiological evidence for distinct vagal pathways mediating CCK-evoked motor effects in the proximal versus distal stomach.

Authors:  Shiho Okano-Matsumoto; James A McRoberts; Yvette Taché; David W Adelson
Journal:  J Physiol       Date:  2010-11-15       Impact factor: 5.182

2.  Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes.

Authors:  N Irwin; P Frizelle; I A Montgomery; R C Moffett; F P M O'Harte; P R Flatt
Journal:  Diabetologia       Date:  2012-07-20       Impact factor: 10.122

3.  CCK-8 and CCK-58 differ in their effects on nocturnal solid meal pattern in undisturbed rats.

Authors:  Miriam Goebel-Stengel; Andreas Stengel; Lixin Wang; Gordon Ohning; Yvette Taché; Joseph R Reeve
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-08-08       Impact factor: 3.619

4.  CCK-58 elicits both satiety and satiation in rats while CCK-8 elicits only satiation.

Authors:  Joost Overduin; James Gibbs; David E Cummings; Joseph R Reeve
Journal:  Peptides       Date:  2014-01-24       Impact factor: 3.750

5.  Effects of cholecystokinin-58 on type 1 cholecystokinin receptor function and regulation.

Authors:  S Vincent Wu; Kaleeckal G Harikumar; Rebecca J Burgess; Joseph R Reeve; Laurence J Miller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09       Impact factor: 4.052

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.